Patients treated with Edwards Lifesciences’ (NYSE:EW) Sapien heart valve had a lower mortality rate and spent less time in hospitals at the two-year mark, according to the data released at this year’s Transcatheter Cardiovascular Therapeutics symposium.
The Partner trial consisted of patients with aortic stenosis, randomized to receive a Sapien valve with transcatheter aortic valve replacement surgery or traditional open-heart surgery.
The U.S. medical device arena is in danger of ceding the throne to countries with friendlier regulatory environments but the system is not irreparable, Dr. Martin Leon said during a lecture at this week’s Transcatheter Cardiovascular Therapeutics symposium in San Francisco.
In early 2009, six medical professional societies got together to write a guide for 180 cardiac revascularization procedures.
A recent survey, however, shows that there may not be consensus amongst the doctors who practice the surgical and percutaneous coronary intervention procedures.